Skip to main content
Perseus Proteomics Inc. logo

Perseus Proteomics Inc. — Investor Relations & Filings

Ticker · 4882 ISIN · JP3836800007 T Professional, scientific and technical activities
Open in API
Filings indexed 56 across all filing types
Latest filing 2026-05-20 Board/Management Inform…
Country JP Japan
Listing T 4882

About Perseus Proteomics Inc.

https://www.ppmx.com/en/

Perseus Proteomics Inc. is a drug discovery biotechnology company specializing in the development of novel antibody-based therapeutics and diagnostics. Originating from the University of Tokyo, the company leverages proprietary antibody technologies and screening platforms to create a pipeline of drug candidates targeting cancer and other diseases. Its business is structured into three main segments: Drug Discovery, which focuses on its internal pipeline; Antibody Research Support, offering services to the research community; and Antibody/Reagent Sales, which provides products like ELISA kits. The company aims to contribute to global healthcare through its advanced antibody-based solutions.

Recent filings

Filing Released Lang Actions
役員人事に関するお知らせ
Board/Management Information Classification · 93% confidence The document is a corporate announcement dated May 20, 2026 from a Japanese issuer (Perseus Proteomics Co., Ltd.) notifying the market of proposed changes to its board of directors and audit committee candidates, including names of new director candidates, resignations, and brief biographies. It does not contain financial data or quarterly results, nor is it a proxy circular, but rather an announcement of board personnel changes. This aligns with the “Board/Management Information” category.
2026-05-20 Japanese
定款の一部変更に関するお知らせ
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a formal notice from Perseus Proteomics Co., Ltd. announcing proposed amendments to its Articles of Incorporation (定款) to be put to a vote at the 26th Annual General Meeting scheduled on 2026-06-24. It details the agenda items, reasons for the changes, and the specific amendments, and is clearly addressed to shareholders to inform them and solicit their votes. This corresponds to materials sent to shareholders to provide information and request votes for a meeting, matching the Proxy Solicitation & Information Statement category.
2026-05-20 Japanese
2026年3月期 決算説明会 質疑応答について
Call Transcript Classification · 85% confidence The document is a Q&A summary from the company’s FY2026 earnings presentation held for analysts and institutional investors, containing detailed questions and answers on pipeline progress, business outlook, and other topics. It is not the financial statements themselves or an announcement of publication, but a transcript-style record of an earnings meeting. Thus, it fits the definition of a Call Transcript (CT).
2026-05-20 Japanese
2026年３月期決算説明会資料
Investor Presentation Classification · 95% confidence The document is titled “決算説明会資料” (Earnings Briefing Materials) for the fiscal year ending March 2026, containing slide‐style presentations on plan vs. actual, financial statements (P/L, B/S), future outlook, and growth strategy. It serves as an investor presentation deck rather than the formal Annual or Quarterly Report itself. This matches the Investor Presentation category (IP).
2026-05-18 Japanese
行使価額修正条項付新株予約権の月間行使状況に関するお知らせ
Regulatory Filings
2026-05-01 Japanese
株式報酬型ストック・オプション（新株予約権）の発行内容確定に関するお知らせ
Regulatory Filings
2026-05-01 Japanese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.